Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Harrington, Lucas B.Doxzen, Kevin W.
Edraki, Alireza
Amrani, Nadia
Sontheimer, Erik J.
Doudna, Jennifer A.
Document Type
Journal ArticlePublication Date
2017-09-07Keywords
Biochemistry, Biophysics, and Structural BiologyCell and Developmental Biology
Genetics and Genomics
Therapeutics
Metadata
Show full item recordAbstract
CRISPR-Cas9 proteins function within bacterial immune systems to target and destroy invasive DNA and have been harnessed as a robust technology for genome editing. Small bacteriophage-encoded anti-CRISPR proteins (Acrs) can inactivate Cas9, providing an efficient off switch for Cas9-based applications. Here, we show that two Acrs, AcrIIC1 and AcrIIC3, inhibit Cas9 by distinct strategies. AcrIIC1 is a broad-spectrum Cas9 inhibitor that prevents DNA cutting by multiple divergent Cas9 orthologs through direct binding to the conserved HNH catalytic domain of Cas9. A crystal structure of an AcrIIC1-Cas9 HNH domain complex shows how AcrIIC1 traps Cas9 in a DNA-bound but catalytically inactive state. By contrast, AcrIIC3 blocks activity of a single Cas9 ortholog and induces Cas9 dimerization while preventing binding to the target DNA. These two orthogonal mechanisms allow for separate control of Cas9 target binding and cleavage and suggest applications to allow DNA binding while preventing DNA cutting by Cas9.Source
Cell. 2017 Sep 7;170(6):1224-1233.e15. doi: 10.1016/j.cell.2017.07.037. Epub 2017 Aug 24. Link to article on publisher's site
DOI
10.1016/j.cell.2017.07.037Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48860PubMed ID
28844692Notes
Full list of authors omitted for brevity. For full list see article.
Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.cell.2017.07.037